Restart Life Sciences Corp. (CSE:HEAL)

Restart Life Sciences Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cost of Revenue	-	-	-	-	0.01
Gross Profit	-	-	-	-	-0.01
Selling, General & Admin	0.86	0.59	0.86	1.4	1.58
Research & Development	0.01	0	0.07	0.12	0.86
Amortization of Goodwill & Intangibles	0	0	0	0	0
Operating Expenses	1.3	0.63	1.21	1.85	2.8
Operating Income	-1.3	-0.63	-1.21	-1.85	-2.8
Interest & Investment Income	-	-	-	0	0
Currency Exchange Gain (Loss)	-	0.01	-	-	-
Other Non Operating Income (Expenses)	0.02	-0.03	-0.02	0.14	-0.04
EBT Excluding Unusual Items	-1.29	-0.65	-1.22	-1.71	-2.84
Gain (Loss) on Sale of Investments	-0.11	-0.14	-	-	0.02
Gain (Loss) on Sale of Assets	-	0.63	-	-	-
Other Unusual Items	-	0.38	-	-0.76	0.13
Pretax Income	-1.39	0.22	-1.22	-2.47	-2.68
Net Income	-1.39	0.22	-1.22	-2.47	-2.68
Net Income to Common	-1.39	0.22	-1.22	-2.47	-2.68
Shares Outstanding (Basic)	34	15	15	14	11
Shares Outstanding (Diluted)	34	16	15	14	11
Shares Change (YoY)	110.37%	9.79%	7.47%	22.91%	117.20%
EPS (Basic)	-0.04	0.01	-0.08	-0.18	-0.24
EPS (Diluted)	-0.04	0.01	-0.08	-0.18	-0.24
Free Cash Flow	-0.72	-0.07	-0.28	-2.41	-1.95
Free Cash Flow Per Share	-0.02	-0.00	-0.02	-0.18	-0.17
EBITDA	-1.3	-0.62	-1.2	-1.84	-2.8
D&A For EBITDA	0	0	0	0	0
EBIT	-1.3	-0.63	-1.21	-1.85	-2.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.